Cameron Reynolds, CEO of Volition Rx, the NYSE-listed company, brings Proactive Investors London an end of quarter catch up with newsflows in three key areas. First there's more news on their new routine blood test to screen for colorectal and prostate cancers which has reduced the need for more invasive colonoscopies and biopsies. Secondly, there's an update on the potential for further revenue streams for Volition once discovery grade assets convert to product grade opportunities. And lastly, how Volition continues to push into veterinary medicine while both well funded and keeping costs down.
View full VNRX profile View Profile